Drugs / Befotinib
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT07709585 | Jul 2026 → Jul 2030 expected | non-small cell lung carcinoma | Guangzhou University of Traditional Chinese Medicine | Not yet recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Befotinib | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07709585 ↗ |
| Route | Oral | “Oral administration, initial dose 75 mg once daily; dose adjusted to 100 mg once daily based on safety and clinical benefit.” NCT07709585 ↗ |